Baseline FDG PET/CT in free breathing versus deep inspiration breath-hold for pediatric patients with mediastinal lymphoma

References

• André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Dörffel W, Rühl U, Lüders H, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol. 2013;31(12):1562–1568.
   PubMed Web of Science ®Google Scholar
• Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the children’s oncology group study AHOD0031. J Clin Oncol. 2014;32(32):3651–3658.
   PubMed Web of Science ®Google Scholar
• Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431–3439.
   PubMed Web of Science ®Google Scholar
• Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the childhood cancer survivor study. Blood. 2011;117(6):1806–1816.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373(26):2499–2511.
   PubMed Web of Science ®Google Scholar
• Maraldo MV, Giusti F, Vogelius IR, European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group, et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2015;2(11):e492–e502.
   PubMed Web of Science ®Google Scholar
• Specht L. Radiotherapy for Hodgkin lymphoma: reducing toxicity while maintaining efficacy. Cancer J. 2018;24(5):237–243.
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, ILROG, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–862.
   PubMed Web of Science ®Google Scholar
• Paumier A, Ghalibafian M, Gilmore J, et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(4):1522–1527.
   PubMed Web of Science ®Google Scholar
• Petersen PM, Aznar MC, Berthelsen AK, et al. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol. 2015;54(1):60–66.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Milgrom SA, Terezakis S, et al. The optimal use of imaging in radiation therapy for lymphoma: guidelines from the international Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2019;104(3):501–512.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, United Kingdom National Cancer Research Institute, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3067.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048–3058.
   PubMed Web of Science ®Google Scholar
• Kluge R, Kurch L, Georgi T, et al. Current role of FDG-PET in pediatric Hodgkin's lymphoma. Semin Nucl Med. 2017;47(3):242–257.
   PubMed Web of Science ®Google Scholar
• Paulino AC, Teh BS. PET-CT in radiotherapy treatment planning. 1st ed. Philadelphia (PA): Saunders Elsevier; 2008. Chapter 4, Biological Target Volume; p. 52–89.
   Google Scholar
• Lundgaard AY, Hjalgrim LL, Rechner LA, et al. TEDDI: radiotherapy delivery in deep inspiration for pediatric patients – a NOPHO feasibility study. Radiat Oncol. 2018;13(1):56.
   PubMedGoogle Scholar
• Aznar MC, Maraldo MV, Schut DA, et al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys. 2015;92(1):169–174.
   PubMed Web of Science ®Google Scholar
• Lundgaard AY, Josipovic M, Rechner LA, et al. The feasibility of implementing deep inspiration breath-hold for pediatric radiation therapy. Int J Radiat Oncol Biol Phys. 2020;106(5):977–984.
   PubMed Web of Science ®Google Scholar
• Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79(1):10–18.
   PubMed Web of Science ®Google Scholar
• Nissen HD, Appelt AL. Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients. Radiother Oncol. 2013;106(1):28–32.
   PubMed Web of Science ®Google Scholar
• Erdi YE, Nehmeh SA, Pan T, et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med. 2004;45(8):1287–1292.
   PubMed Web of Science ®Google Scholar
• Specht L, Nordentoft AM, Cold S, For the Danish National Hodgkin Study Group, et al. Tumor burden as the most important prognostic factor in early stage Hodgkin’s disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988;61(8):1719–1727.
   PubMed Web of Science ®Google Scholar
• Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(9):1735–1743.
   PubMed Web of Science ®Google Scholar
• Akhtari M, Milgrom SA, Pinnix CC, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018;131(1):84–94.
   PubMed Web of Science ®Google Scholar
• Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131(13):1456–1463.
   PubMed Web of Science ®Google Scholar
• Pike LC, Kirkwood AA, Patrick P, et al. Can baseline PET-CT features predict outcomes in advanced Hodgkin lymphoma? A prospective evaluation of UK patients in the RATHL trial. Hematol Oncol. 2017;35:37–38.
   PubMedGoogle Scholar
• Barrington SF, Meignan M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med. 2019;60(8):1096–1102.
   PubMed Web of Science ®Google Scholar
• Milgrom SA, Elhalawani H, Lee J, et al. A PET radiomics model to predict refractory mediastinal Hodgkin lymphoma. Sci Rep. 2019;9(1):1322.
   PubMedGoogle Scholar
• Bayne M, MacManus M, Hicks R, et al. Can a mathematical formula help define a radiation target volume using positron emission tomography? In regard to black et al. Int J Radiat Oncol Biol Phys 2004;60:1272–1282). Int J Radiat Oncol Biol Phys. 2005;62(1):299–300.
   PubMed Web of Science ®Google Scholar
• Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342–1348.
   PubMed Web of Science ®Google Scholar
• Meignan M, Itti E, Gallamini A, et al. FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging. 2015;42(4):623–633.
   PubMed Web of Science ®Google Scholar
• Girinsky T, Ghalibafian M, Bonniaud G, et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol. 2007;85(2):178–186.
   PubMed Web of Science ®Google Scholar
• Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–1839.
   PubMed Web of Science ®Google Scholar
• Berthelsen AK, Holm S, Loft A, et al. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging. 2005;32(10):1167–1175.
   PubMed Web of Science ®Google Scholar